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Pregnant patients with mechanical heart valves have a significant risk of thromboembolism 
which may be life threatening and continuous therapeutic anticoagulation is essential. Oral 
warfarin is the most effective anticoagulant; however, administration during pregnancy is 
associated with complications to both mother and fetus. Alternatives include low molecular 
weight heparin or unfractionated heparin. Low molecular weight heparin has a variable efficacy 
and is associated with life threatening thrombosis formation and unfractionated heparin requires 
administration via continuous intravenous infusion. The presence of differing opinions on the 
most effective regime with the least risk to mother and fetus highlights the difficulties 
confronting obstetricians when anticoagulation is required during pregnancy.     
Objectives  
Primary aim:  1) To describe the perinatal mortality rate in a group of pregnant women requiring 
anticoagulation therapy for the treatment of prosthetic heart valves and to compare it to the 
background rate for the population during the study period. 2) To describe the maternal mortality 
rate in the study group and to compare it to the background rate for the population during the 
study period. Secondary aims: To describe the specific fetal, neonatal and maternal 
complications attributable to the use of anticoagulation therapy in pregnancy and to make 
recommendations pertaining to counseling of pregnant women with prosthetic heart valves 













Cases were recruited from 2004 to 2008. Fifty one pregnancies in forty nine  mothers with 
mechanical heart valves were studied in a retrospective review. Patients followed a standard 
protocol which applies to all pregnant women with mechanical heart valve prostheses managed 
at Groote Schuur Hospital.  
Results  
The perinatal mortality rate was 47.6 and was higher than the background rate of 31.52. There 
were 2 stillbirths and no neonatal deaths. There were 9 miscarriages with a total pregnancy loss 
rate of 21%.There were 6 cases of warfarin-associated embryopathy.  There was 1 maternal 
death. The maternal case fatality rate was 1.9%. The maternal complication rate was 19%: 2 
cases of valve thrombosis, 1 case of thrombophlebitis, 1 case of infective endocarditis and 3 
cases of post partum haemorrhage.  
Conclusion  
Women with mechanical heart valves require therapeutic anticoagulation. There is a significant 
risk of a warfarin-associated embryopathy if warfarin is used between weeks 6 to 12 of 
pregnancy. The risk of fetal loss is greater in patients with mechanical heart valves. Intravenous 
unfractionated heparin is an effective anticoagulant and offers an alternative to warfarin. The 
anticoagulant regime adopted in this audit offers the best maternal protection with limited 
complications. Emphasis must be placed on adequate preconception counseling. Patients should 
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Valvular Heart Disease 
Valvular heart disease represents a significant burden within our health care system. This 
condition remains an obstetric challenge, especially in developing countries such as South 
Africa. Pregnancy represents a state of physiological thrombophilia and it is therefore assumed 
that this time period is associated with an increased risk of thrombosis. The treatment of valvular 
heart disease may have an adverse effect on the pregnancy. 
The incidence of cardiac disease among pregnant women is estimated at 1% of the total pregnant 
population
1
. Pre-existing medical conditions constitute one of the five major causes of maternal 
mortality in South Africa
2
. One of the ten key recommendations made in the 
document, Saving Mothers: Fourth Report on Confidential Enquiries into Maternal Deaths in 
South Africa, lists the need for protocols on the management of important medical conditions 
during pregnancy. One such condition is cardiac disease
2
 and valvular heart disease is included 
in this high risk group.     
In developing countries, rheumatic fever is the most common cause of cardiac valve lesions and 
the incidence of rheumatic heart disease remains high in these resource-poor settings.
3
 In South 
Africa the incidence is estimated at 23.5/100000/year and 68% of these patients are female
4
. 
Sixty three and a half percent of all pregnant women with cardiac disease suffer from rheumatic 
heart disease
1
. Other causes of cardiac valve lesions include congenital abnormalities (9%), 
infection as in the case of bacterial endocarditis, or occasionally de novo in adult life5. Long-term 











replacements. Usually a prosthetic (metallic) valve is used.  
Patients who have undergone a prosthetic heart valve replacement have a significant risk of 
thromboembolism which may be life threatening and life-long anticoagulation is essential 
6, 7, 8, 9
. 
This will reduce the risk of thromboembolism by 75%
10
.  
The risk of thrombus formation is even greater during pregnancy due to the manifestations of a 
physiological thrombophilia
6, 7
. This problem is of considerable interest to obstetricians and 
gynaecologists, as many female patients with replaced mechanical heart valves are of 
childbearing age, and prosthetic valve replacements complicate 38% of pregnancies
1
. 
Normal pregnancy maintains a physiological thrombophilia; the endogenous anticoagulant 
system is less effective and it is therefore assumed that the risk of prosthetic valve thrombosis is 
increased during this time period. The risk of maternal mortality from thromboembolism in a 





mechanical mitral valves have the greatest risk of thrombosis
11, 12, 13
. For pregnant patients with 
mechanical heart valves anticoagulation is a necessity
14, 15, 7
. However, all anticoagulation 
options available pose high risks to both the mother and fetus.  
Patients with bioprosthetic valves have less risk of thrombosis, but a greater risk of 
decompensation and valve failure, especially during pregnancy. Premature valve failure is a well 
documented complication in young people with bioprostheses
7 
and it seems that pregnancy can 
accelerate this process. These valves are considered to be less durable
14, 16 
and may only last 10 
to 15 years. Generally it is not advised to place a bioprosthetic valve in young women who may 
plan to conceive. Mechanical valve replacement may be the only alternative and emphasis should 
















Warfarin is a derivative of 4-hydroxycoumarin, and antagonises vitamin K-dependent gamma 
carboxylation of clotting factors II, VII, IX and X
17
. It causes a functional deficiency of Vitamin 
K
12
. Due to its wide range of action it is a highly effective anticoagulant and offers the greatest 
maternal protection. It is taken as an oral dose and close monitoring is essential. This is achieved 
with a blood sample, measuring the prothrombin time, which is expressed as the 
internationalised normalised ratio (INR), and has now been accepted as the standardised 
method
18
. The target INR range in patients with mechanical h art valves is 2.5-3.5
9
. Keeping the 
INR within the therapeutic range is paramount to its safety and efficacy. If too low, a clot can 
form and if too high there is the risk of bleeding. It is important to be aware of the fact that when 
taking an anticoagulant, haemorrhage may still occur even in well-controlled cases, where the 
INR is less than 3
10
. Very few patients have completely stable INR’s remaining within the 
therapeutic target range. Regulation of INR levels is a difficult challenge in non-pregnant 
patients and pregnancy only serves to exacerbate the problem. The efficacy of warfarin may be 
further reduced by the ingestion of other drugs, for example erythromycin, fluconazole, 
fluoxetine, and thyroid hormone as well as some foods rich in vitamin K such as garlic, ginseng 




Warfarin has a molecular weight of less than 1000 and crosses the placenta
20
. The immature liver 
of the fetus cannot counteract the anticoagulant effect. In normal pregnancy the fetal liver has 













. Warfarin binds to albumin and only the free fraction produces the 
anticoagulant effect. Bilirubin competes with warfarin on this albumin-binding site. The fetus 
has a high concentration of bilirubin and fetal albumin has a higher affinity for fetal bilirubin. 





mother is within therapeutic range the fetus is essentially overdosed
21
.  
The use of warfarin in pregnancy is associated with an embryopathy, characterised by nasal 
hypoplasia and epiphyseal stippling
22







. The embryopathy is an abnormality of cartilage formation, related to abnormal calcium 
deposition. Warfarin disrupts vitamin K regeneration, by inhibiting the enzyme epoxide 
reductase. Vitamin K is necessary in the synthesis and carboxylation of glutamic acid residues of 
osteocalcin in the osteoblasts Gla matrix protein
20, 21
. Osteocalcin is found in embryonic and 
adult bone and is crucial in the early calcium deposition in bone in the developing embryo. The 
inhibition of osteocalcin results in chondrohypoplasia punctata (stippling) and nasal hypoplasia
20, 
23,15






. If exposure 
continues into the second and third trimester warfarin use can cause central nervous system 





incidence of the embryopathy is estimated to be low, less than 5%, (3.4% - 6.4%) and children 
born with the embryopathy associated with warfarin usage, in fact have low morbidity
9, 15, 21
. 
Additional documented complications associated with warfarin use during pregnancy are those 




, preterm delivery and
 
neonatal death 














Warfarin may cause bleeding in the fetus and this anticoagulant effect is especially dangerous at 
the time of delivery when trauma caused by the delivery process may result in intracerebral 
haemorrhage
24, 15, 9
. Fetal haemorrhage has been associated with both a vaginal delivery and 
caesarean section
14
. Some studies suggest that caesarean section would decrease this risk
24
.  The 
risk of bleeding to both mother and baby is greatest at delivery. 
The risk of poor fetal outcome as well as the risk of warfarin-associated embryopathy is dose-




documented poor outcome in 30 of the 70 pregnancies studied, and there were 2 embryopathies 
in full-term infants. Poor outcome (spontaneous abortion, still birth and embryopathy) was 
related to a warfarin dosage of more than 5mg per day. Warfarin dosage of less than 5mg per day 
had a good outcome. Vitale looked retrospectively at the effect of warfarin dosage on the fetus
21
. 
This audit documented 58 pregnancies requiring warfarin, which was used throughout 
pregnancy. This study showed a statistically significant relationship between warfarin dosage 
and fetal complications. As the dose increased so did the risk to the fetus. Included in this, is the 
risk of fetal loss due to spontaneous abortion (mostly in the first trimester)
 21
. The warfarin 
embryopathies, of which there were two, occurred in babies born to mothers taking 6.5mg daily 
on one occasion and 7.5mg per day on the other. This view was not supported by a study done by 
Meschengieser
6
, where the relationship between warfarin dose and poor outcome with or without 
the embryopathy was not found to be present. This quoted relationship between dose and risk of 




The dosage of warfarin does not influence the rate of early pregnancy loss
6
. Warfarin does not 















The teratogenic effect of warfarin may be prevented if this agent is not used in the first trimester 
between weeks 6 to 12 of pregnancy
6, 21
. Heparin is made from intestines of mammals and does 
not cross the placenta
22, 9, 10, 15
. In an attempt to avoid the fetal complications, heparin has been 
used as a substitute for warfarin, either throughout pregnancy or only during the first trimester 
and towards the end of the third trimester. Administration of heparin in the first trimester of 
pregnancy eliminates the risk of the warfarin embryopathy
21 
and use towards the end of 
pregnancy reduces the risk of maternal and fetal haemorrhage
22, 15












Unfractionated heparin binds to anti-thrombin III and thus inhibits thrombin and in addition 
inactivates clotting factor Xa. The anticoagulant effect is measured by the APTT ratio (activated 
partial thromboplastin time), aiming for 1.5-2.5 x the control at midpoint between doses
9
. 
Laboratories must be correctly calibrated when calculating the APTT7. Heparin may 
demonstrate a varied anticoagulant effect and also interacts with various proteins (platelet factor 
4 and Von Willabrand Factor, which increase in pregnancy). The use of antiXa as a monitoring 
assay may be more useful. Aim for anti-factor Xa levels of at least 0.3-0.59. 
Continuous intravenous unfractionated heparin infusion offers the most consistent level of 
anticoagulation
14
. This regime is inconvenient, as it requires admission to hospital and a 
prolonged in-patient hospital stay in the first trimester and again at the end of the third trimester
9
. 











warfarin has been discontinued
8, 11, 24
 and therefore it is important to admit the patient as near as 
possible to 36 weeks gestation and to replace the warfarin with heparin at this point because of 
the high incidence of preterm labour in patients with prosthetic heart valves
14
. If the mother goes 
into labour whilst still anticoagulated on warfarin she should be given fresh frozen plasma
8
 and 
Vitamin K, followed by an emergency caesarean section to decrease the risk of intracranial 
haemorrhage in the neonate. Elective caesarean section at 38 weeks has been considered. This 
would allow for a brief interruption of warfarin ingestion a few days before the scheduled 
delivery with no need for IVI heparin infusion
24, 12
. Unfractionated heparin can be injected 
subcutaneously, but this regime is associated with a high risk of maternal thrombosis.  
 
Low molecular weight heparin 
Low molecular weight heparin (LMWH) is made from unfractionated heparin and also does not 
cross the placenta. It is administered subcutaneously. It does not bind to antithrombin III, but is 
does inactivate clotting factor Xa. It offers the potential for a once daily dose due to its longer 
plasma half life
15, 9, 14
. LMWH has a better bioavailability and absorption from subcutaneous 
administration than unfractionated heparin
14 
and may offer a more consistent protection
6
. It has 
been used successfully in pregnant patients in the treatments of coagulopathies such as 
antiphospholipid syndrome, factor V Leiden mutation and deep vein thrombosis
26
. LMWH is 
also associated with a lower rate of spontaneous abortions
14
.  
However, the fact remains that LMWH has been associated with thrombosis of mechanical heart 
valves if used for thromboprophylaxis in pregnancy and its use in this situation has not been 
unequivocally recommended
22, 9, 11
. There is limited data, but some authors would suggest that 











valves provided treatment is aggressive and along an adjusted-dosage regime
9,25.
 LMWH must be 
monitored using the anti-Xa levels and dosages adjusted accordingly. This regime of 
aggressively adjusted dosage of LMWH throughout pregnancy is one of three suggested by the 
American College of Chest Physicians 2004.  
Many authors remain hesitant regarding the efficacy of unfractionated heparin or low molecular 
weight heparin in preventing thromboembolism and suggest the efficacy is much lower than that 
of warfarin. It is clear that the efficacy has not yet been fully established
14, 24, 7, 9
.  The concern is 
that an effective dosage regime and accurate monitoring of the anticoagulant effect during 
pregnancy remains unclear 
6 
and is further complicated by the fact that the pharmokinetics of 
heparin are altered in pregnancy. The increased plasma volume and increased renal clearance in 
pregnancy influence the volume of distribution
9, 27
. Lower doses of heparin carry the risk of 





The known side effects of heparin include two types of thrombocytopaenia. Early onset 
thrombocytopaenia (occurring within 3-5 days) usually resolves spontaneously and may go 
unnoticed by the patient. Late onset, (after about 6 days) results in a drastic drop in platelet level, 
marked symptoms and in most cases necessitates the discontinuation of heparin 
12
. Long-term 
heparin use is associated with osteoporosis, which is mostly asymptomatic and vertebral 
fractures occur in approximately 3% of the patient population
9
, while 30% may be left with 
decreased bone mineral densities
15
. Three percent of non-pregnant patients on long-term heparin 
develop immune IgG-mediated thrombocytopaenia
15
. LMWH has been associated with less 













When using heparin, the risk of haemorrhage is always present. In a systematic review by Chan 





 quotes a similar rate: The risk of bleeding is 2.5% during any 
pregnancy requiring anticoagulation and the risk of bleeding in patients using unfractionated 
heparin is equivalent at 2% 
9
. 
 It is important to note that the there is no benefit to using heparin in the first trimester to prevent 





a spontaneous abortion rate of 37.9% on warfarin throughout pregnancy, similar to that quoted 
by Salazar (37.5%) using subcutaneous heparin
24
.  The miscarriage is thought to be due to 




Anticoagulation Regimes  
In general, clinicians worldwide are in strong agreement that all patients with mechanical heart 
valves must be anticoagulated, including during pregnancy. The debate revolves around the 
choice of anticoagulant and the timing of the prescription. Differing opinions only serve to 
highlight the difficulties confronting obstetricians when faced with the dilemma of required 
anticoagulation during pregnancy.  
Unfractionated heparin has been used subcutaneously in a number of studies and in most cases 
carried a high rate of adverse outcome in the mother - thromboembolism being one of the most 
common and dangerous. The incidence of thromboembolism in pregnant patients with 
mechanical heart valves using subcutaneous heparin ranges from 5% - 33% 
17, 24, 15, 7
. Frewin
17 











interval APTT of 2.0 - 2.55 x the control. The APTT was checked daily until the anticoagulant 
effect had been established and weekly thereafter. The study done by Salazar 
24
 used a lower 
dosage of subcutaneous heparin according to a dose-adjusted regime, aiming for an APTT level 
of 1.5 - 2.5 x the control. During this study there were two maternal deaths due to 
thromboembolism and the study was prematurely terminated and it was concluded that 
administration of subcutaneous heparin was not effective in preventing thromboembolism during 
pregnancy. Oakley
7
 found 13 valve thromboses in 151 pregnancies in patients with mechanical 
heart valves, 6 of which were fatal, and 10 occurred with the use of subcutaneous heparin 
administration (2 with warfarin and 1 whilst no anticoagulant was given). Complications were 
higher in women with mechanical heart valves and mostly in those using heparin. There was no 
difference in fetal outcome between the patients on heparin throughout pregnancy or those on 
warfarin throughout pregnancy. However, women taking heparin and then warfarin were more 
likely to have a healthy baby than those taking either heparin or warfarin throughout. This study 
concluded that, “heparin was neither effective nor safe for long-term use in pregnancy bringing 
an increased risk of both thromboembolism and bleeding and a hazard to mother and fetus”. 
Chan agreed: In this systematic review of the literature
25
 it was reported that when heparin was 
used in the first trimester the risks of maternal thromboembolism, and therefore death, more than 
doubled. This large literature review quoted a 3.9% thromboembolism complication rate in 
women taking warfarin compared to a rate of 9.2% in women taking unfractionated heparin 





 documented a rate of 4.92% for embolic events in 
pregnancies where oral anticoagulation was replaced with subcutaneous heparin, compared to 











only discontinued 15 days before delivery. Early fetal loss was much the same between the two 
groups. This study concluded that fixed or adjusted-dosage of subcutaneous heparin was not 
sufficient to prevent thromboembolism and the protection given was not constant. Mohamed
13 
documented 3 valve thromboses (1 fatal) and 3 instances of uterine haemorrhage in 71 
pregnancies in patients requiring anticoagulation. The complications were ascribed to the use of 
heparin as an anticoagulant. This study concluded that heparin was less effective than oral 
anticoagulants in preventing thrombosis. Bates
15
 suggested a risk of 9.2% for valve thrombosis 
when using unfractionated heparin from week 6 to 12. The regime least associated with 
complications was that of warfarin throughout pregnancy. However, to minimize the risk of the 
warfarin-associated embryopathy, the authors suggest stopping warfarin between 6-12 weeks 




This view that heparin is not effective as an anticoagulant in pregnant patients was not supported 
by a small number study published in the Journal of the American College of Cardiology in 
1986, where adjusted-dose subcutaneous heparin was used in 18 pregnancies in 16 women with 
mechanical heart valves. There were no instances of thromboembolism in the mothers and no 
congenital abnormalities reported in the babies
29
.  
Administering UFH as a continuous intravenous infusion to offer a more consistent 




suggests substituting IVI 
unfractionated heparin for warfarin from week 6 to 12 and then again in the last two weeks of 
pregnancy. Oakley
7
 recommends heparin only be used in the last two weeks of pregnancy while 











The use of LMWH has been explored in an attempt to find a regime that is convenient, effective 
and safe, whilst providing an anticoagulant medication that does not cross the placenta. Yinon
27
 
discusses the option of adjusted doses of subcutaneous LMWH in pregnancy for women with 
mechanical heart valves. This study looked at 23 pregnancies over a 10-year period. The heparin 
was administered subcutaneously twice a day. Anti-Xa levels were taken every two weeks,  
4 hours post administration and the dose adjusted accordingly. This regime continued until 
delivery. The authors reported 1 maternal death from a valve thrombus, which developed on a 
replaced aortic valve. They concluded that warfarin was still considered the best anticoagulant, 
but suggested adjusted-dose subcutaneous LMWH as an alternative option.    
McLintok and North
30
 agree that warfarin is the safest option in pregnancy for the mother. 
However, in pursuit of a more acceptable regime, their retrospective audit looked at women 
using enoxeparin (LMWH). They reported 5 cases of thromboembolism related to enoxeparin 
(10.6%) and noted that sub-therapeutic anti-Xa levels were a documented problem. There were 
no cases of thrombosis related to warfarin usage. However there was a much higher rate of fetal 
loss in the group using warfarin. The authors were happy to recommend enoxeparin together 
with low dose aspirin as an acceptable treatment regime
30
.     
The discrepancies between centers on management protocols for pregnant patients with 
mechanical heart valves, highlights the difficulties facing the clinician as he or she takes into 
account the intricate balance between the risks facing the mother and those affecting the fetus. 
From a review of the literature it is clear that there is both consensus and concern regarding the 
embryopathy associated with the administration of warfarin, especially in doses greater than 
5mg, during the first trimester. Most clinicians would suggest discontinuing warfarin from week 











the setting of an aggressive, dose-adjusted regime, does not offer sufficient anticoagulant cover 
to the mother. Admitting the patient for IVI unfractionated heparin administration will offer a 
more consistent anticoagulant cover as well as allow for close monitoring of the mother and 
fetus, and would be the ideal choice if it did not require a long in-patient hospital stay and expose 
the patient to the associated risks of intravenous administration, namely those of 
thrombophlebitis and infective endocarditis. A question still remains regarding the use of low 
molecular weight heparin as an anticoagulant in pregnant women with mechanical heart valves.   
 
Pregnancy in a patient with a mechanical heart valve is fraught with danger. Each patient should 
be fully informed of the risks associated with each anticoagulant available and counseled 
correctly on the possible maternal and fetal complications. In order to advise patients in our 
clinical setting we require documented information pertaining to the complication rates 
associated with the current treatment regime.    




















1. To describe the perinatal mortality rate in a group of pregnant women requiring anticoagulant 
therapy for the treatment of prosthetic heart valves and to compare it to the background rate for 
the population during the study period.  
2. To describe the maternal mortality rate in the study group and compare it to the background 
rate for the population during the study period. 
 
Secondary Aim  
1. To describe the specific fetal and neonatal complications attributable to the use of 
anticoagulant therapy in pregnancy. 
2. To describe the specific maternal complications attributable to the use of anticoagulant therapy 
in pregnancy. 
3. To make recommendations pertaining to counselling pregnant women with prosthetic heart 















Fifty one pregnancies in forty nine mothers with mechanical valve prostheses were studied in a 
retrospective review.  
Ethics approval 
The study was approved by the University of Cape Town Ethics Committee. 
Participants  
Cases were recruited from February 2004 to November 2008.  
In the case of the mothers, the patients were identified when they booked their pregnancy at the 
Groote Schuur Hospital antenatal clinic.  
Folders of the mothers and the neonates were reviewed retrospectively.  
All of the patients attended the Groote Schuur Hospital antenatal clinic in Cape Town, South 
Africa. All of the patients had metallic, mechanical valve replacements and because of this were 
automatically referred to this unit from outlying primary or secondary units once pregnancy was 
confirmed.  
All patients required life-long anticoagulation and all were treated with the coumarin derivative 
oral anticoagulant known as warfarin. All patients were treated within either the Groote Schuur 












The Management Protocol 
Antenatal  
 
Patients followed a standard protocol which applies to all pregnant patients with mechanical 
valve prostheses managed at Groote Schuur Hospital. Once pregnancy was confirmed, the 
gestational age was calculated using a baseline ultrasound. If the patient attended the clinic 
(booked the pregnancy) within the first trimester she was admitted to the ward from week 6 until 
the end of week 12. If the first contact with the clinic was after 6 weeks, but before the end of the 
12
th
 week she was admitted immediately. As an inpatient she received intravenous (IVI) 
unfractionated heparin. This was administered as a continuous rate-controlled infusion, aiming to 
keep the APTT within the therapeutic range of 1.5 to 2.5 x the control. The APTT was monitored 
daily via a venous blood sample and the heparin infusion rate adjusted accordingly. If adjustment 
was required the change was made within one hour of the blood sample and the APTT checked 
again 6 hours after the adjustment. The cannula was changed every three days to avoid 
thrombophlebitis. The patient was attended to daily (and more often if necessary) by the registrar 
in charge of the ward.   
At the end of the 12
th
 week, the patient was restarted on warfarin under cover of heparin until the 
international normalised ratio (INR) was within the therapeutic range of 2.5-3.5. Once this was 
achieved, the patient was discharged on warfarin, to continue as an outpatient. The INR was 
checked weekly at a designated clinic. The patient’s warfarin dose was adjusted if necessary on 











If the INR was sub-therapeutic at any point during the pregnancy, the patient was again admitted 
to the ward for intravenous unfractionated heparin infusion until the INR reached a therapeutic 
level.   
All patients who attended the clinic before 22 weeks had a routine 22-week fetal anomaly scan in 
the Fetal Medicine Unit. This scan routinely screened for fetal anomalies and also specifically 
documented any evidence of a warfarin-associated embryopathy.  
Patients were again admitted to the ward at 36 weeks to receive IVI unfractionated heparin as 
before. The warfarin was stopped and the APTT monitored as described previously.  
 
Labour and Delivery 
Patients awaited spontaneous labour unless there was a clear indication for operative delivery or 
induction of labour. At the onset of labour, the heparin was stopped immediately, to be restarted 
no sooner than 6 hours after delivery. Patients delivered in the Labour Ward at the Groote 
Schuur Hospital Maternity Unit. Indications for delivery by caesarean section were the same as 
those applied to the general population and included fetal hypoxia (documented as fetal distress), 
previous caesarean sectio , failed induction of labour and failure to progress.  















Postnatal Care  
The patient was transferred to the High Care area of the Labour Ward for 24 hours for 
observation. Heparin was restarted 6 hours postpartum as a continuous infusion monitored as 
previously via the APTT taken as a venous blood sample.    
If the patient remained stable she was transferred to the Postnatal Ward and restarted on warfarin 
under cover of heparin until the INR reached a therapeutic level.  
All patients were encouraged to breastfeed unless there was an indication for formula, as in the 
case of an HIV-positive mother choosing to formula feed.  
 
Folder review 
Folders were reviewed on the hospital premises. INR results were obtained from the patients’ 
records or from the computer laboratory system. Data was captured on a spreadsheet. 
 
Recorded Information  
Preterm delivery was documented if the baby was delivered before 37 completed weeks 
gestation.  
INR was considered therapeutic if the value was between 2.5 and 3.5. 











The site of the mechanical valve was recorded but not the type, as in most cases this was not 
known. The patient’s usual dosage of warfarin was recorded as well as the dosage with which 
they continued in the pregnancy. It was noted if the patient developed a complication or had to 
be admitted out of the normal routine for INR stabilisation. 
Miscarriages were documented if the pregnancy was lost before 28 weeks gestation. Stillbirth 
was documented if the pregnancy was lost at or after 28 weeks gestation.  
A paediatric medical officer examined the neonates routinely. The examining doctor recorded 
warfarin-associated embryopathy as positive if the baby was noted to have a flat nasal bridge.  
Any other abnormalities were recorded and noted. The miscarriages were not examined for 




















The analysis of the 51 pregnancies in 49 patients revealed the following: 
Demographics  
Table 1: Demographics 
      (n) 
Average age  (years)    28 
Replaced valve:  Mitral only   27 
    Aortic only   6 
  Aortic and mitral  14 
                Pulmonary only   1 
  Mitral Aortic Tricuspid  1 
Replacement pre-pregnancy (yrs)    9.8 
The ages of the patients ranged from the youngest of 14 years to the oldest of 42 years. The 
average number of years from the valve replacement to the current pregnancy was 9.4 years, the 
shortest being 2 years and the longest being 25 years.  
The majority of the patients (27) had replaced mitral valves. The type of valve prosthesis used 
was not recorded, as this information could not be extracted. The average age at which the valve 
had been replaced was 18 years, the youngest being 5 years of age and the oldest 36 years. The 
average number of years prior to the pregnancy at which the valve had been replaced was  
10 years. The smallest interval between the valve replacement and the current pregnancy was  
2 years and the longest interval was 25 years. Only 14 of the 49 patients were in their first 











All patients met the criteria for life-long anticoagulant therapy. Warfarin was the therapy of 
choice and the prescribed medication in all cases. In 14 of the 51 pregnancies patients had 
discontinued (defaulted) their treatment and were not on warfarin at first antenatal clinic 
attendance (booking visit). This was noted and the patients were included in the analysis.  
One patient had a miscarriage at 6 weeks, it was not noted if she was on warfarin at the time of 
miscarriage.  
Table 2: Obstetric data and outcome 
Mean gestational age at booking (months)  17.2 (weeks) 
Mean gestational age at delivery  32.7(weeks)  
Primigravid     14 (n) 
Stillbirths     2 (n) 
Neonatal deaths     0 (n) 
Miscarriages     9 (n) 
Embryopathy     6 (n) 
Caesarean Sections    17(n) 
Normal vaginal deliveries   19(n) 
Assisted deliveries    2(n) 
Perinatal mortality rate    47.6  













Table 3: Indications for caesarean section: CTG= cardiotocograph 
Indications for caesarean: (n) 
Pathological CTG  9 
Previous caesarean  4 
Labour not progressing 2 
Failed induction of labour 2 
 
The protocol at Groote Schuur Hospital is to allow for vaginal birth in all patients unless there is 
a medical indication for operative delivery. The caesarean section rate was 33% in this group of 
patients.  
Outcome  
Perinatal mortality rate  
(Number of fetal deaths + neonatal deaths) / (live births + Stillbirths) x 1000 
(2+ 0)/ (40+ 2) x 1000 = 47.6   
The background perinatal mortality rate for the peninsula maternal and neonatal service = 31.52     
Maternal mortality rate 
Number of maternal deaths / number of deliveries x 100 000 live births 













Maternal Mortality Rate for the peninsula maternal and neonatal service for the time period 
2005-2007, is 67.7 per 100 000 live births.  
Case fatality rate 1/51 =1.9% 
Fetal Complications 
Warfarin-associated Embryopathy 
There were 6 cases of documented warfarin-associated embryopathy.  
Rate of 11.7% 
All 6 were identified as nasal hypoplasia. All 6 cases were warfarin-exposed during the first 
trimester. Five of the 6 patients were taking more than 5mg of warfarin a day and 1 patient was 
on an unknown dose but had conceived whilst taking warfarin. Four of the 6 cases first attended 
(booked) at an advanced gestational age, which was too late to be admitted for intravenous 
heparin (IVI) infusion in the first trimester. One patient (taking 7.5mg daily) booked at 10 weeks, 
subsequently only receiving unfractionated heparin from 10 weeks to 12 weeks gestation.  
One patient (taking 7.5mg and 10mg on alternate days), 2 patients (taking 7.5mg and 5mg on 
alternate days) and 1 patient (taking 7.5mg daily) completely missed the opportunity for first 
trimester heparin by only booking (first attendance) at 12 weeks, 24 weeks, 15 weeks and 20 
weeks respectively.  In the case where the exact dosage of warfarin was not known, it was clear 
that the pregnancy had been conceived whist the patient was taking warfarin. This patient’s first 
attendance (booking visit) was within the first trimester, at 7 weeks and she was admitted until 
12 weeks for heparin administration. Four of the 6 cases were identified on the routine antenatal  











late for a detailed FA scan, and 1 baby born with nasal hypoplasia, had a normal FA ultrasound. 
Only 1 infant with a warfarin-associated embryopathy was referred to the Red Cross War 
Memorial Children’s Hospital for follow up. One was born with bilateral talipes equinous which 
was not considered to be associated with warfarin ingestion. This patient’s sister had two 
children with the same abnormality. The infant was referred to the orthopaedic clubfoot clinic for 
bilateral posterior release, which was successful. 
 
Table 4: Indicating the relationship between warfarin dose and the associated 







Heparin during T1 
Nasal hypoplasia 7.5mg Yes Yes: weeks 10-12 
Nasal hypoplasia 7.5mg Yes No 
Nasal hypoplasia 7.5mg/10mg Yes No 
Nasal hypoplasia 5mg/7.5mg Yes No 
Nasal hypoplasia Not known Yes Yes: weeks 7-12 
Nasal hypoplasia 5mg/7.5mg Yes No 
 
Of the babies born without signs of the warfarin-associated embryopathy, 21 of the mothers were 
on more than 5mg of warfarin per day and of these 21, only 6 received heparin in the first 
trimester.   













Neonatal deaths  
There were no neonatal deaths 
Stillbirths and Early Pregnancy Loss 
The total fetal wastage was 21%  
Stillbirths 
Two pregnancies ended with the delivery of a stillborn infant. One occurred at 28 weeks and one 
at 34 weeks gestation. One patient with a MVR (mitral valve replacement) had defaulted 
warfarin for over 10 years. She was on no other medication. She attended the clinic for the first 
visit at 27 weeks. During the second trimester, she was prescribed 7.5mg daily, but required 
admission at 31 weeks for a sub-therapeutic INR. She was screened for syphilis as part of the 
routine antenatal screening tests and was found to have a positive result: (VDRL positive) with a 
titre 1:16. She had only received 1 bicillin injection and was not fully treated. She went into 
spontaneous labour at 34 weeks and delivered a macerated stillborn baby. There were no signs of 
warfarin embryopathy and the placental histology did not reveal any further information. 
The second patient delivered a stillborn infant at 28 weeks, with signs of a warfarin-associated 
embryopathy. Her warfarin dosage was 7.5mg and 10mg on alternate days for mechanical aortic 
valve prosthesis. Her first attendance at the clinic (booking visit) was at 12 weeks. She continued 
on warfarin at doses of 7.5mg and 10mg on alternate days. The 22-week scan showed nasal 
hypoplasia and at 28 weeks an intrauterine fetal demise (IUFD) was diagnosed. She underwent 













Table 5: Stillbirths 
Gestation Warfarin 
dose 
Heparin in T1 Warfarin 
embryopathy 
Cause  
28 weeks  7.5mg/10mg No Yes Unknown 
34 weeks  Defaulted No No Unknown 
 
Detailed patent information: Appendix II  
Miscarriages 
There were 9 miscarriages: 17.6% of the total 51 pregnancies.  
Six of the 9 occurred in the second trimester and 3 in the first trimester. 
 Two out of the total 9 patients who miscarried presented with spontaneous vaginal bleeding. 
Early pregnancy ultrasound identified 6 of the remaining 7 by indicating an absent fetal heart and 
1 case was an anembryonic pregnancy. Seven of the 9 miscarriages were warfarin-exposed at the 
time of the miscarriage. One patient had discontinued (defaulted) her medication. This fetus had 
an identified anomaly, that of multiple pterigium syndrome. In the case of the other patient, the 
documentation of her warfarin regime was omitted. It was unclear whether or not she was 
compliant at the time of the miscarriage at 6 weeks.    
Four of the total 9 patients were taking additional medication such as a diuretic, digoxin or an 











vascular accident and there was 1 case of documented Human Immunodeficiency Virus (HIV) 
(CD4 count of 182). This patient was not on anti-retroviral therapy.  
The gestational ages at the first clinic attendance (booking visit) ranged from 6 weeks to  
21 weeks with a mean of 14 weeks. Four of the patients booked in the first trimester and 5 in the 
second trimester.  
Five patients were taking more than 5mg of warfarin daily and all 5 conceived whilst taking 
warfarin. Only 2 of these 5 patients booked the pregnancy at an early enough gestational age to 
receive IVI heparin during the first trimester. One patient was on exactly 5mg per day and also 
attended (booked) too late to receive heparin in the first trimester. One patient was on 2.5mg and 
5mg on alternate days. This patient had a fetal abnormality (multiple pterigium syndrome) and 
had discontinued (defaulted) her treatment. Two patients (both first trimester miscarriages) were 
on an unknown dose of warfarin. One had conceived whilst taking warfarin - the dose was not 
documented - and she presented at 7 weeks. She was commenced on IVI heparin, but miscarried 
6 days later. The other presented for the first time at 6 weeks with an incomplete miscarriage.  
Five of the 6 second trimester miscarriages occurred in patients who had booked too late for first 
trimester heparin administration.  
There was 1 documented fetal abnormality (multiple pterigium syndrome). The remaining 8 
fetuses were not examined for abnormalities and the cause of the miscarriage was not explored.  
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Table 7: Miscarriages: 
D=diuretic, dig= digoxin, ACE-I=ace-inhibitor, CVA=cerebral vascular accident, FA=fetal 











6 weeks Unknown  6 weeks No D, ACE-I 
7 weeks  Unknown 
dose  
7 weeks No ACE-I 
7 weeks +6d  5mg/10mg 7 weeks   Yes: from week 7  None 
14 weeks  Defaulted 14 weeks No FA 
16 weeks  5mg Unbooked  No D, Dig 
17 weeks  10mg 6 weeks Yes: from week 6 – 12 None 
19 weeks  5mg /7.5mg 19 weeks  No D 
21 weeks  7.5mg 21 weeks No CVA 
21 weeks  5mg/7.5mg 15 weeks No HIV CD4=182 
 
















Preterm delivery  
 
There were four instances of preterm delivery.  
Of these 4 cases, one was due to an unrelated cause, that of pre-labour preterm rupture of 
membranes at 32 weeks, the patient went into spontaneous labour and delivered a 1635g baby. 
The remaining 3 were due to maternal complications related to the underlying cardiac condition 
and the cause of the preterm delivery was iatrogenic. These 3 mothers had additional co-
morbidities such as atrial fibrillation (2 of the 3) and the development of valve thromboses  
(2 of the 3). All 3 were on additional medications such as an anti-hypertensive, digoxin, diuretics 
and β-blockers. All 3 of these patients delivered prematurely due to maternal complications 
related to the underlying maternal co-morbidity, and all 3 were delivered by emergency 
caesarean section. One patient delivered at 35 weeks and the baby weighed 1965g, the second 























Table 8: Gestational age, precipitating factor and infant weight in preterm deliveries in 
patients taking Warfarin in pregnancy:  
PPROM= pre-labour preterm rupture of membranes. MVR= mitral valve replacement. 












Warfarin dose  
 
Infant weight  

















alternate days  
 
2115g 
























Additional fetal complications 
 
Two babies were considered to be growth restricted, which equated to 5% of the total live births.  
Both were delivered by emergency caesarean section after an attempted induction of labour. The 
first at 37 weeks, the infant weighed 2390g, and the second at 38 weeks and the infant weighed 
2435g. Both fetuses were warfarin–exposed in the first trimester, although the first patient 
attended at 8 weeks and had the benefit of 4 weeks of intravenous heparin infusion during the 
first trimester. Both babies progressed well and were discharged to the mother on day 2 and 8 
respectively.       
One neonate developed a cephalohaematoma. The most likely cause of this complication was the 
assisted vacuum delivery. This patient had a MVR and was on a warfarin dose of 5mg and 7.5mg 
on alternate days. She was fully heparinised for 4 weeks prior to delivery; from 36 weeks to 40 
weeks, when she went into spontaneous labour. A 2580g baby was delivered by vacuum 
extraction and sustained a cephalohaematoma. The infant progressed well and was discharged 
from the nursery to the mother on day 1.  
















The maternal complication rate was 13%.   
 
Maternal Death 
There was 1 maternal death. This is a case fatality rate of 1.9%.  
This patient had a MVR. She was carrying a twin pregnancy. She was taking warfarin in doses of 
5mg and 7.5mg on alternating days, having conceived on warfarin. She was also taking a 
diuretic. She booked at 9 weeks, and was admitted for continuous unfractionated heparin 
infusion until the end of the first trimester. She was discharged on 5mg warfarin daily at 12 
weeks. She died at 14 weeks gestation. She was an outpatient at the time of death. No post 
mortem was requested and the cause of death is unknown.    
 
Valve Thrombosis 
There were 2 cases of maternal valve thrombosis: which equates to 3.9 % of the total 51 
pregnancies.  
Both cases occurred in patients with mitral valve prostheses. One patient had a metallic mitral 
valve prosthesis and the other had a metallic aortic and mitral valve replacement, as well as a 
fistula between the aorta and right atrium. Valve thromboses occurred in both patients whilst on 
warfarin at 35 weeks and 32 weeks respectively. Both had therapeutic anticoagulation levels. 
The valve thromboses occurred close to the time of delivery.  Both delivered by emergency 











pulmonary edema).  Both patients survived and one went on to have an emergency valve 
replacement 3 days postpartum.  
 
Thrombophlebitis 
There was 1 case of thrombophlebitis: which equates to 1.9% of the total 51 pregnancies. 
 
This occurred whist the patient was receiving continuous intravenous unfractionated heparin 
infusion. She had a total of 30 days of IVI heparin. She went into spontaneous labour at term and 




There was 1 case of infective endocarditis: which equates to 1.9% of the total 51 pregnancies.  
 
This patient was 28 years old. She had conceived on warfarin and was admitted during the first 
trimester until 12 weeks for IVI heparin. She had a total of 38 days in the first trimester on IVI 
heparin and was discharged on warfarin 5mg and 7.5mg on alternating days. She was admitted at 
37 weeks for IVI heparin and had a total of 28 days of IVI administration. She developed an 
endocarditis, with no associated thrombophlebitis, but did have a documented lower urinary tract 
infection. She went into spontaneous labour at term and delivered a 3450g baby by caesarean 












There were 3 cases of postpartum haemorrhage:  which equates to 5.8% of the total 51 
pregnancies. Two of the 3 cases were patients who had delivered vaginally and 1 case was after a 
delivery by caesarean section. All 3 patients were on heparin at the time. 
Detailed patient information: Appendix VI  
Table 9: Summary: Outcome 
Caesarean section    17  33% 
Preterm Delivery    4  7.8% 
Warfarin associated embryopathy 6  11.7% 
Neonatal death    0  0% 
Perinatal mortality    2  47.6 
Miscarriages    9  17.6% 
Growth restriction   2  5% 
Maternal Death   1  2% 
Valve thrombus   2  4% 
Endocarditis    1  2% 
Thrombophlebitis   1  2%   
Post partum haemorrhage  3  5.8% 
 
Additional co-morbidities documented in the 51pregnancies are listed in Table 10 and include 











epilepsy (1 patient), and HIV infection (4 patients). One patient had undergone an embolectomy 
previously and 3 had undergone repeat valve replacements prior to the current pregnancy.  
Three patients were in chronic atrial fibrillation (AF). Of these 3 patients; 1 had an 
uncomplicated pregnancy and went into spontaneous labour at term. She delivered by caesarean 
section for fetal distress and not for a maternal indication. The other 2 patients developed 
complications related to the underlying maternal condition. One booked late at 23 weeks, having 
defaulted treatment for 6 months. She was admitted at 32 weeks in fast AF and was induced at 
34 weeks. She had a caesarean section for fetal distress. Fast (uncontrolled) AF, congestive 
cardiac failure and sepsis complicated the post partum period.  
Thirteen patients were on diuretics, 6 on an antihypertensive, 2 patients were on a β-blocker and 
2 on digoxin.   
Table 10: Additional co-morbidities 
ITP    1 
CVA previously   2 
Epilepsy   1 
HIV    4 
Embolectomy previously 1 
Redo valve replacements 3 













Table 11: Additional medication 
Diuretics    13 
Anti-hypertensive  6 
B blockers   2 
Digoxin   2  
 
Of the 51 pregnancies, 36 patients were on warfarin at their first clinic visit (booking visit). The 
deduction made from this information was that they had conceived whilst taking warfarin. In  
1 case it had not been recorded if the patient was taking warfarin at the time of her first 
presentation. This patient had a miscarriage at 6 weeks; her first recorded INR was not 
therapeutic. Of the 36 patients on warfarin at booking, 13 of them booked early enough (i.e. 
before 12 weeks) to be admitted within the first trimester for unfractionated heparin infusion to 
avoid the warfarin-associated embryopath .   
No miscarriages occurred during the period when the patient was receiving IVI unfractionated 
heparin.   
Fourteen of the total of 51 were not compliant and were not taking warfarin at first clinic 
attendance (booking). One patient had defaulted for 4 months and 1 patient for more than 10 
years. There were no miscarriages or stillbirths in this group.  
Thirty seven of the 51 patients were not admitted within the first trimester for heparin. Of these 
37, 23 were taking warfarin at booking but booked after 12 weeks and were too late to be 











this group. Fourteen patients were not on warfarin at booking and not admitted during the first 
trimester as they booked too late (after 12 weeks).  
Of the 37 patients who were not admitted for first trimester heparin administration, all booked 
too late to receive intravenous heparin (i.e. after 12 weeks) except for the patient who presented 
and miscarried at 6 weeks. Of these 37, 2 pregnancies ended in second trimester miscarriages, 
and there was 1 termination of pregnancy at 17 weeks for medical reasons, which has been 
documented as a miscarriage. 
All of the patients, bar 2, were prescribed warfarin during the second trimester. One patient 
booked very late at 36 weeks and was admitted immediately for IVI heparin. One patient was 
lost to follow up during the second trimester. She went into spontaneous labour at term and 






















Pregnant women with mechanical heart valves have a significant risk of both thromboembolism 
and cardiac decompensation during pregnancy. Effective and safe management throughout the 
pregnancy requires careful consideration of the effects of treatment on both the mother and fetus. 
This consideration should be applied to the choice of anticoagulant prescribed during the 
pregnancy.  
The number of patients included in this audit is comparable to current literature relating to 
anticoagulation therapy in pregnant patients with mechanical valves. There was a wide range of 
ages in this group of patients and only 14 were primigravid patients indicating that women may 
choose to conceive more than once within their lifetime even with the high risk nature of their 
underlying cardiac condition. The average age of the valve replacement surgery was 18 years, 
near the beginning of the reproductive period. This emphasizes the need for a multidisciplinary 
approach in the management of these patients involving cardiologists, obstetricians and 
anaesthetists
28, 11
 as well as effective and timeous preconception counseling. 
All patients in this group met the criteria for life long anticoagulant therapy. Warfarin was the 
therapy of choice and the prescribed medication in all cases. Warfarin remains the anticoagulant 
of choice as it has the widest range of action by antagonizing clotting factors II, VII, IX and X. 
Normal haemostasis is achieved through the clotting system, which is a cascade of reactions in 
which coagulation factors activate each other. Clotting factor X is central to the common 











factor (factor III) initiates haemostasis by forming an active complex with factor VII. This 
complex may then directly activate factor X or follow the route via activated factors XII, XI and 
IX to activate factor X. The final part of the cascade is a common pathway in which activated 
factor Xa together with factor V convert prothrombin to thrombin. Thrombin activates factor 
XIII (cleaving fibrinogen to fibrin), which stabilizes the fibrin threads to form a clot. Platelets 
aggregate and adhere to the clot
10, 33
.  
If unchecked the clotting system would continue to build clot on top of clot. Thrombin has two 
positive feedback mechanisms. It activates factors V, VII and XIII as well as activating platelets, 
reinforcing their aggregation. To regulate the coagulation cascade and to prevent continued clot 
formation there is an endogenous anticoagulant system. Firstly, thrombin itself is regulated by 
fibrin, which has the ability to absorb and inactivate up to 90% of the thrombin formed. 
Secondly, there is endogenous heparin cofactor II and antithrombin to which thrombin binds and 
is subsequently inactivated. The third mechanism to control clot formation is proteins C and S. 
Thrombin binds to thrombomodulin and thus activates protein C, which binds to protein S and 
inactivates factors VIIIa and Va. Fourthly, plasmin (cleaved from plasminogen by tissue type 
plasminogen activator, tPA) breaks down fibrin. tPA is in itself inactivated by PAI-1 and PAI-2, 
produced by the placenta and the decidua.
10, 33
   
Normal pregnancy maintains a physiological thrombophilia. The endogenous anticoagulant 
mechanism is less effective and there is an increased concentration of clotting factors VII, VIII, 
IX and X. There is also an increase in fibrinogen and prothrombin (resulting in an increase in 
thrombin) as well as a decrease in the level of protein S and resistance to protein C. Platelet 
consumption is quicker and clot breakdown less efficient, due to the production of PAI-1 and 











trauma) all exist as normal physiology in pregnancy and these physiological changes lead to an 
even greater risk of thromboembolism
6, 9, 28, 7, 10
. For patients with mechanical prosthetic heart 
valves pregnancy represents a period of extreme risk and anticoagulation is essential. All patients 
recruited in this audit required life-long anticoagulation therapy including for the duration of 
pregnancy. The anticoagulant of choice is warfarin, which is substituted by unfractionated 
intravenous heparin from week 6 to 12 and from week 36 to delivery. This substitution is done in 
an attempt to limit complications in the fetus, namely miscarriage, stillbirth, warfarin-associated 
embryopathy, and intracerebral haemorrhage during delivery.  
In addition to these changes in the clotting system there are also changes within the 
cardiovascular system during normal pregnancy, namely adjustments to the blood volume, 
cardiac output and peripheral vascular resistance. These necessary adjustments are important to 
note as they may lead to decompensation during pregnancy even in patients who have previously 
tolerated the heart lesion well
28
. 
The physiological changes in pregnancy result in an increased cardiac output (mainly due to 
increased blood volume) and decreased peripheral vascular resistance.
 
There is a 50% increase in 
blood volume, which begins in the first trimester and peaks at 20-24 weeks
16, 28
. The increase in 
pulse rate and stoke volume lead to an increase in cardiac output of 40%, peaking in the  
25
th
 week of pregnancy.
 
Labour leads to an increase in cardiac output of 15% in the first stage 
and 50% during the second stage. As the uterus contracts, blood shifts from the myometrium into 
the general circulation. This is called auto-transfusion
11
. Postpartum, the patient remains at risk 
of decompensation as the cardiac output increases by 60-80% due to the blood shift from the 
empty uterus and placental bed into the general circulation and the relief of pressure on the 











rate and cardiac output that occur in normal pregnancy may lead to congestive cardiac failure in 
women with valvular heart disease
10
. However, it has been found that the pregnancy may be 
well- tolerated if ventricular function is adequate and the replaced valve is functioning well
13
. 
Pregnancies in women with a poor baseline function, classified as New York Heart Association 
(NYHA) grade 3 (breathlessness on minimal exertion) or NYHA 4 (breathlessness at rest), are 
associated with a higher incidence of maternal, fetal and neonatal morbidity and  
mortality
3, 14, 10,16
. The maternal outcome depends largely on the state in which the woman enters 
the pregnancy and in general the overall tolerance to pregnancy depends on her general health 
and reserve
3, 8. 





effects are more likely with an ejection fraction of less than 40%, aortic stenosis with an area 
under the valve of less than 1.5cm
2
, mitral stenosis with an area under the valve of less than  
2 cm
2
, a NYHA class of 3 or 4 and a history of a previous cardiac event
16
. A reliable predictor of 
poor fetal outcome is left ventricular dysfunction and a poor baseline function
16
. Information on 
the type of replaced valve and the underlying cardiac condition and baseline functional level of 
the patients in the group studied was not available and could not be included in this audit. 
However there were significant co-morbidities documented: Twenty three of 49 women were on 
additional cardiac medication, 3 patients were in chronic atrial fibrillation, 3 had undergone 
repeat cardiac valve surgery and 1 had had a previous embolectomy. Three out of the 4 
documented preterm deliveries were iatrogenic on the background of the deteriorating cardiac 
and medical condition of the mothers.  
The site of the replaced valve plays a role in reducing or increasing the risk to the pregnancy
14
. 
Replaced mechanical mitral valves have the greatest risk of thrombosis
11, 12, 13
. All of the patients 











replaced mitral valves.  
The mode of delivery of choice in patients with mechanical heart valves is vaginal delivery with 




In this group the caesarean section rate of 33% is acceptable, noting that 
the operative deliveries were done for obstetric indications which would apply to all pregnant 
patients.     




The percentage of 
21% fetal wastage (stillbirths and miscarriages) is marginally higher than that quoted in the 
literature. There were 2 stillborn infants in 51 pregnancies and no neonatal deaths. The perinatal 
mortality rate was significantly higher in this group of patients compared to the rate for the 
general patient population. This can be accounted for in two ways: This patient group was a 
small number study and this group of patients is identified as a high risk group. The perinatal 
mortality rate of 31.52 is quoted for the perinatal maternal and neonatal service which has a 
higher number of pregnancies and births and would include both low and high-risk pregnancies.   
The use of warfarin in pregnancy is associated with an embryopathy, characterized by nasal 
hypoplasia and epiphyseal stippling
22
, especially when used within weeks 6-12 of pregnancy
6
. 
The rate of warfarin embryopathy of 11.7% in this group is higher than that quoted in the 
literature (3.4% - 6.4%). Bates estimated a 6.4% rate of embryopathy in live births when 
warfarin was used throughout pregnancy
15
. Cotrufo estimated an incidence of warfarin-




 Vitale quoted a rate of 3.4%
 21 
and Jeffrey quoted a rate 
below 5%
9  
when the fetus had been exposed to warfarin between weeks 6-12. The most notable 
fact in this group is that 4 out of the 6 patients with a documented embryopathy presented after 
the first trimester, having exposed the fetus to warfarin throughout the first trimester, and that the 











as they presented after the 6
th
 week, at 7 and 10 weeks respectively. This indicates a significant 
problem within our patient population: the patient’s first attendance at the antenatal clinic is at an 
advanced gestational age, despite the high-risk nature of their pregnancy. The mean gestational 
age at the first clinic visit (booking visit) for all 51 pregnancies was 17.2 weeks, well into the 
second trimester, and dangerously late in the pregnancy for this high-risk group. Five of the 6 
cases of warfarin-associated embryopathies occurred in patients taking more than 5mg of 
warfarin per day. In 1 case the dose is unknown. Cortufo and Vitale describe an association 
between warfarin dosage and the risk of a fetal embryopathy, reporting that 5mg a day or less has 
a lower risk of damage to the fetus
22, 11
. In the study by Cortufo
20 
, 30 out of 71 pregnancies had a 
poor outcome and there were 2 embryopathies in term infants. This was specifically related to 
dose, with 27 patients out of the 30 receiving more than 5mg of warfarin daily. Warfarin dosage 
of less than 5mg per day had a good fetal outcome. Vitale 
21
 documented 58 pregnancies in 43 
patients, aiming for INR of 2.5 to 3.5. The patients were kept on warfarin throughout the 
pregnancy, and there was a statistically significant relationship between warfarin dosage and 
fetal complications. Based on the outcome of this study the authors suggested that those patients 
usually taking more than 5mg of warfarin per day, should decrease their dose to 5mg or less per 
day and aim for INR of 2 to 2.5 to limit the risk to the fetus. The specific dosage of warfarin does 
not influence the rate of early pregnancy loss
6
. On the basis of these findings, some authors 
suggest that women on warfarin dosage of 5mg or less should continue warfarin use throughout 
pregnancy stopping only close to delivery. If the patient desires normal vaginal delivery then 
intravenous heparin should be used in an in-patient setting for the last two weeks of the 
pregnancy. If the patient declines warfarin then the suggestion is for IVI heparin in the first 













An association between warfarin dosages and the associated embryopathy cannot be drawn from 
this audit as there were 36 babies born without documented signs of the embryopathy and 21 of 
these were exposed to more than 5mg per day. Of these 21, only 6 presented early enough to 
receive first trimester heparin infusion.   
Intravenous use of unfractionated heparin in the first trimester of pregnancy eliminates the risk of 
the warfarin embryopathy
22
. Of the 51 pregnancies in this audit, 36 patients were on warfarin at 
the time of their first presentation and of these 36, only 13 presented early enough (before  
12 weeks) to receive heparin to avoid the warfarin-associated embryopathy.   
Of great concern is the fact that 14 patients presenting in the total 51 pregnancies were not taking 
warfarin at the time of their first clinic attendance. This is a poor compliance rate. And of the 36 
patients compliant on warfarin only 13 attended early enough to be eligible for heparin in the 
first trimester. The remainder (23) presented after 12 weeks.  
The figure quoted in this audit for the rate of early pregnancy loss (17.6%) is smaller than that 
quoted in the literature (>20%). Of the 9 documented miscarriages, 7 occurred at the time of 
warfarin exposure. One miscarriage occurred in a patient who had discontinued (defaulted) 
treatment. This fetus had a documented anomaly and it is assumed that this, rather than the 
underlying maternal cardiac condition, was the cause of the fetal wastage. There was no early 
fetal loss in patients receiving IVI heparin during the first trimester. It has been found that if 
warfarin is used throughout pregnancy there is a higher percentage of fetal loss through stillbirth 
and spontaneous miscarriage as well as neonatal death
25
. In those patients who conceived on 
warfarin and did not receive heparin during the first trimester, the miscarriage rate was 26%. 











rate of pregnancy loss and replacing warfarin with unfractionated intravenous heparin may 
protect against early pregnancy loss. This finding is in contradiction to recent literature, where 
authors found no difference in early pregnancy loss when using heparin in the first  
trimester
6, 12, 25, 21, 24
. 
Noting that 37 of the 51 pregnancies were not treated with heparin during the first trimester, this 
smaller percentage of fetal wastage (17.6%) is unexpected. This may be explained by taking into 
account that in 14 of the 51 pregnancies, patients were non-compliant which raises the question 
of the true compliance rate of the 23 patients who were documented to be taking warfarin, but 
who presented after the first trimester. In fact, the lower rate of fetal wastage may be due to 
erratic compliance within this group of patients; if this assumption is true it puts these patients at 
an even greater risk and gives rise to grave concern with respect to maternal anticoagulant 
protection.      
The cause of the maternal death was unknown. It occurred whilst the patient was taking warfarin 
within the second trimester and her anticoagulation levels were therapeutic at the time. In the 
absence of a postmortem investigation no conclusive deduction can be made.  
The maternal complication rate of 13% is not higher than figures quoted in similar audits. There 
were 2 cases of maternal valve thrombosis: 3.9 % of the total 51 pregnancies. Both cases 
occurred in patients with mitral valve prostheses. One patient had a metallic mitral valve 
prosthesis and the other had a metallic aortic and mitral valve replacement. This rate is lower 
than that described in the literature, and there were no cases of thromboembolism whilst the 











The fact that there was only 1 case of thrombophlebitis and 1 case of infective endocarditis can 
possibly be ascribed to the protocol of changing the venous access site every three days whilst 
the patients are receiving heparin. This is necessary to maintain sterility and limit the risk of 
infection.  
The continuous intravenous heparin infusion offers a consistent level of maternal 
anticoagulation
14
, but requires prolonged in-patient hospitalisation. Whilst this carries a cost both 
financially for the medical service provider and socially for the patient, it offers adequate and 
effective anticoagulation to the mothers and reduces the risk to the fetus and neonate.  The 
efficacy of low molecular weight heparin in pregnant patients with mechanical heart valves at 
this stage remains uncertain and its use in this setting is not advised.  
 
Limitations of this audit are noted as the inability to determine the cause of the maternal death 
and of the stillbirths. Postmortems were not carried out in all three of these cases. It would be 
preferred if the cause of the stillbirths and maternal death could have been determined as this 
would have value to the outcome of this audit. Deaths ascribed directly to the use of 
anticoagulation would influence the findings and recommendations of this study.      


















 The regime adopted for the management of pregnant patients with mechanical heart valve 
prostheses described in this audit, offers the best maternal protection with limited complications. 
Replacing warfarin with unfractionated heparin as a continuous intravenous infusion from week 
6 to 12 provides adequate anticoagulation for the mother whilst protecting the fetus from 
complications associated with warfarin ingestion and reducing the risk of early pregnancy loss. 
Replacing warfarin with unfractionated heparin infusion from 36 weeks until delivery provides 
adequate anticoagulation protection for the mother and protects the baby from warfarin- 
associated complications such as intracerebral haemorrhage. The concern pertaining to this group 
of patients is the fact that a significant number do not comply with treatment and a significant 
number present for the first time in the pregnancy after 12 weeks gestation, thereby eliminating 
the opportunity to protect the fetus against the potentially harmful effects of warfarin exposure 
during the first trimester. This audit indicates that the maternal complication rate was not higher 
than that reported in other studies and there was no early pregnancy loss associated with the use 
of heparin and no neonatal haemorrhage associated with the regime. However the regime 
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1: Warfarin associated Embryopathy  
1) The first patient had a mechanical aortic valve replacement (AVR) and mitral valve 
replacement (MVR). She was taking 7.5mg warfarin daily and conceived whilst taking 
warfarin. Her first attendance (booking visit) was at 10 weeks gestation and she was 
admitted for the remainder of the first trimester for unfractionated heparin (UFH) via 
continuous intravenous infusion. She was on no additional medication. The 22-week fetal 
ultrasound documented nasal hypoplasia in the fetus. The patient continued through the 
second trimester on warfarin 5mg and 7.5mg on alternate days. She required one 
additional admission to correct a sub-therapeutic anticoagulation (sub-therapeutic INR) 
level. At 36 weeks she was admitted for continuous intravenous heparin infusion. She 
delivered by caesarean section (C/S) at term for failure to progress in labour and a 











referred to the local tertiary children’s hospital (Red Cross Children’s War Memorial 
Hospital) for further management. 
 
2) This patient had a MVR and was taking 7.5mg warfarin daily. She was on no additional 
medication. Her first attendance (booking visit) was at 20 weeks gestation. She was 
taking warfarin at conception. The 22-week fetal anomaly scan of the fetus identified a 
mid-facial defect with possible nasal hypoplasia. The patient was admitted at 37 weeks 
for intravenous heparin infusion and went into spontaneous labour at 41 weeks. A 3420g 
baby was born, with nasal hypoplasia, however the infant was not referred for further 
management or follow up. 
  
3) The third patient is also included and discussed in the stillbirth group. She had an AVR 
and was on warfarin 7.5mg and 10mg alternate days. She was also taking an 
antihypertensive (ACE-inhibitor) and a diuretic. Her first attendance (booking visit) was 
at 12 weeks having conceived on warfarin and at this gestation it was too late to receive 
continuous heparin infusion. She continued during the second trimester on warfarin at 
doses of 7.5mg and 10mg on alternate days. The 22-week detailed fetal ultrasound 
showed nasal hypoplasia and at 28 weeks an intrauterine fetal demise (IUFD) was 
diagnosed. She was induced and delivered a 945g stillbirth which had features of a 
warfarin embryopathy. 
 
4) The next patient had a mechanical MVR and was also in chronic atrial fibrillation (AF). 











prescribed spironolactone, atenolol, an ACE-inhibitor and digoxin. Her first attendance 
(booking) was at an advanced gestation (late) at 24 weeks and she was taking warfarin at 
the time of conception. She was not adequately anticoagulated at her first attendance. 
This gestation was too late for heparin administration and also too late for a detailed fetal 
anomaly scan. She was admitted at 31 weeks complaining of difficulty in breathing, was 
in respiratory distress and atrial fibrillation and developed a valve thrombus. She had an 
emergency caesarean section (C/S) at 32 weeks and a baby of 2115g was delivered. The 
neonate developed HMD. The baby had dysmorphic features and this was considered to 
be due to warfarin ingestion. The infant was discharged on day 19. The patient went on to 
have an emergency valve replacement 3 days after delivery 
 
5) The fifth patient had a MVR and AVR. At first attendance (booking visit) her dose of 
warfarin was not known, although she had conceived on warfarin. She booked at 7 weeks 
and was admitted until 12 weeks for continuous heparin infusion. She then continued 
taking 5mg and 7.5mg warfarin on alternate days. The 22-week fetal ultrasound showed 
bilateral talipes equinous and a flat nasal bridge. The bilateral club feet were thought to 
be of possible familial origin, as the patient’s sister had two children with the same 
abnormality. The rest of the scan revealed no spina bifida and a normal central nervous 
system. She had two additional admissions for chest pain and antepartum haemorrhage. 
She was admitted at 36 weeks for continuous IVI UFH infusion and went into 
spontaneous labour at 39 weeks. She delivered a baby of 3105g by vacuum extraction. 











was thought not to be associated with warfarin ingestion. The infant was referred to the 
orthopaedics clubfoot clinic for bilateral posterior release, which was successful. 
  
6) The last patient had an AVR. She was on warfarin 5mg and 7.5mg on alternate days. She 
fist attended (booked) at 15 weeks having conceived whilst taking warfarin and at this 
gestational age is was too late for first trimester heparin infusion. She had a normal fetal 
anomaly scan. During the second trimester and into the third, she continued on 7.5mg and 
10mg on alternate days. She had two extra admissions for high INR levels and a urinary 
tract infection. She was admitted at 36 weeks for heparin and delivered a 2537g baby by 




2 pregnancies ended in the birth of a stillborn infant. One occurred at 28 weeks gestation and the 
other at 34 weeks.  
1)  One patient had a MVR. She had discontinued her warfarin and had not taken it for over 
10 years. She was on no other medication. Her first attendance (booking visit) was at an 
advanced gestation (late) at 27 weeks, which was too late in the pregnancy to receive IVI 
UFH and too late for a detailed fetal anomaly scan.  During the second trimester, she was 
prescribed warfarin at a dose of 7.5mg daily and required admission at 31 weeks to 











antenatal screening and was found to have a positive test result: (VDRL positive) with a 
titre 1:16. She received only 1 bicillin injection and was not fully treated. She went into 
spontaneous labour at 34 weeks and delivered a macerated stillbirth there were no signs 
of warfarin-associated embryopathy and the placental histology did not reveal any further 
information. 
 
2) The second patient has been discussed as a warfarin embryopathy case. She was taking 
warfarin 7.5mg and 10mg alternate days for mechanical aortic valve prosthesis (AVR). 
She was also taking an antihypertensive (ACE-inhibitor) and a diuretic. Her first 
attendance (booking) was at 12 weeks having conceived on warfarin and this was too late 
to be admitted for the continuous UFH infusion. She continued taking warfarin at doses 
of 7.5mg and 10mg on alternate days. The 22-week fetal ultrasound showed nasal 
hypoplasia and at 28 weeks an intrauterine fetal demise (IUFD) was diagnosed. She was 




The 6 second-trimester miscarriages are described as follows:  
1) This patient had a MVR and was taking warfarin in doses of 2.5mg and 5mg on alternate 
days. She had discontinued (defaulted) her medication and had only taken the warfarin 











gestational age of 14 weeks and a fetal ultrasound indicated there was no fetal heart 
activity. Labour was induced. The post mortem investigation showed multiple pterigium 
syndrome. 
 
2) This patient had a metallic MVR and AVR and a bioprosthetic (tissue) tricuspid valve 
replacement (TVR). She was on warfarin 5mg daily and also taking a diuretic and 
digoxin. She presented at 16 weeks gestation with vaginal bleeding and had not yet 
registered for antenatal care. The pregnancy ended in a miscarriage, and the patient 
required an evacuation of the uterus.  The fetus was not examined for any abnormalities.   
 
3) This patient miscarried at 19 weeks. She had a MVR and was taking warfarin 5mg and 
7.5mg on alternate days, having conceived whilst taking warfarin. She was also taking a 
diuretic. She continued taking warfarin during the second trimester at dosages of 5mg and 
7.5mg on alternate days. She registered and first attended (booked) at 19 weeks gestation 
and the absence of fetal heart activity was diagnosed on the routine ultrasound. The 
labour was induced and she delivered a 480g fetus. It was not examined for 
abnormalities.  
 
4) This patient miscarried at 21 weeks. She had a MVR and AVR and the medical 
comorbidities included a CVA (cerebral vascular accident). She was taking warfarin 
7.5mg daily. She conceived whilst taking warfarin and attended (booked) too late in the 











showed absent fetal heart activity. The INR was 4.0. The labour was induced and she 
delivered a 320g fetus that was not examined for and abnormalities.  
 
 
5) This pregnancy ended in a miscarriage at 21 weeks. The patient had a MVR and was 
taking 5mg and 7.5mg warfarin on alternate days. She tested positive for Human 
Immunodeficiency Virus (HIV) and had a low CD4 count of 182. She was not on 
antiretroviral therapy. She booked at 15 weeks, too late in the pregnancy for first 
trimester heparin. The patient was admitted at 17 weeks for sub-therapeutic INR. The 
fetal ultrasound at 21 weeks showed absent fetal heart activity and the labour was 
induced. She delivered a 340g fetus and placental histology revealed mild ischemia. No 
definitive cause for the miscarriage was found.   
 
6) This patient had a MVR. She was on 10mg of warfarin daily. She booked the pregnancy 
at 6 weeks gestation and was admitted for heparin until the end of the first trimester. She 
was subsequently put onto 5mg and 7.5mg warfarin on alternate days. At 17 weeks a fetal 
ultrasound showed absent fetal heart activity. She had an induction of labour and 
delivered a 100g fetus. The fetus was not examined for abnormalities.  
 
The first trimester miscarriages occurred as follows:  
1) This patient was on warfarin 7.5mg and 10mg alternate days for an AVR. She booked at 
7 weeks and was admitted for heparin infusion until the end of the first trimester. The 











spontaneous miscarriage 6 days after the scan and required an evacuation of the uterus. 
The miscarriage was not investigated and no placental histological analysis was 
requested.    
 
2) This patient had a particularly poor obstetric history. She had a replaced aortic valve and 
mitral valve. Repeat surgery had been done on the aortic valve in 1996. The 4 preceding 
pregnancies had ended in miscarriages: 3 first trimester miscarriages and 1 second 
trimester miscarriage. It is unclear whether or not she was taking warfarin at this time. 
She was however on an antihypertensive and a diuretic. She was diagnosed with an 
anembryonic pregnancy at 6 weeks. She had an evacuation of the uterus.  
 
3) This patient had an AVR and MVR. Her usual dose of warfarin had not been 
documented. She had conceived whilst taking warfarin. She was also taking an ACE-
inhibitor. She was admitted during the first trimester for heparin. An ultrasound at  
7 weeks showed absent fetal heart activity. She had an evacuation of the uterus. The 
placental tissue was not sent for histological analysis.   
 
Appendix IV 
Preterm Deliveries  
1) The first patient had a mitral valve replacement (MVR) and was taking 10 mg of warfarin 
daily with the exception of Sunday when she took 15 mg. She was also taking digoxin 











gestation (late), at 28 weeks, having conceived on warfarin. The pregnancy was 
complicated by preterm pre-labour rupture of membranes and she went into spontaneous 
labour at 32 weeks and delivered a 1635g infant. The infant was treated for pneumonia 
and recovered well and was discharged at approximately one month old.  
2) The second patient delivered at 35 weeks. She had an aortic valve replacement (AVR) 
and a MVR having undergone a redo (repeat surgery) MVR in 1995. She was taking 5mg 
and 10mg of warfarin on alternate days, which was decreased to 5mg daily during the 
pregnancy. She was adequately anticoagulated. She was also taking digoxin, an ACE-
inhibitor and spironolactone. She booked at an advanced gestation, at 24 weeks, having 
conceived on warfarin. She was admitted at 32 weeks and induced at 35 weeks and 
delivered a 1965g baby by emergency caesarean section (C/S) for fetal hypoxemia made 
evident on a pathological cardiotocograph tracing (also termed fetal distress). The patient 
was transferred to the Intensive Care Unit after delivery for a valvular thrombosis. The 
baby was thought to be growth restricted but progressed well and was discharged on day 
8 in a healthy condition. 
 
3) The third patient had an emergency caesarean section at 32 weeks. She had a MVR and 
was also in atrial fibrillation (AF) she was on warfarin 5mg and 7.5mg on alternate days 
and was also on spironolactone, atenolol, an ACE-inhibitor and digoxin. She booked at 
an advanced gestational age (late), at 24 weeks having conceived on warfarin. She was 
not adequately anticoagulated at this first attendance. She was admitted at 31 weeks with 
the complaint of shortness of breath, was in AF and developed a valve thrombosis. She 











Hyaline Membrane Disease (HMD), but progressed well and was discharged day 19. The 
patient went on to have an emergency valve replacement on the third day after delivery.  
4) Patient number 4 was induced at 34 weeks. She had MVR and AVR was also in atrial 
fibrillation. She was taking atenolol and furosemide (lasix), but had defaulted warfarin 
therapy for 6 months. The patient was not taking warfarin at the time of conception. She 
booked (first attendance) late (at an advanced gestational age) at 23 weeks. She was not 
adequately anticoagulated at booking. She was put onto 5mg and 7.5mg warfarin on 
alternate days. The pregnancy was complicated by three extra admissions for sub- 
therapeutic anticoagulation levels (low INR) and fast AF. She was induced at 34 weeks 
and delivered a 2145g infant by emergency caesarean section for fetal distress. Post 
delivery she went into cardiac failure, was in fast AF with sepsis caused by MRSA. The 
baby was discharged well on day 17.   
 
Appendix V  
Additional fetal complications  
Two babies were considered to be growth restricted, which equated to 5% of total live births.  
Of these, 1 patient had a MVR. She was taking 2.5mg and 5mg warfarin on alternate days. She 
was also on a β-blocker and a diuretic. She booked at 8 weeks having conceived on warfarin and 
was admitted for continuous heparin infusion through the first trimester until 12 weeks. She had 
a normal 22-week scan and continued on warfarin 2.5mg and 5mg alternate days. She was 
admitted at 36 weeks for heparin and was induced at 37 weeks. She delivered a 2390g baby by 











discharged from the nursery 2 days after delivery and discharged home with the mother on day 
10.    
 
The second patient was 40 years old. She had a mechanical aortic valve. She was on warfarin 
2.5mg and 5mg alternating days. She booked at 16 weeks, too late for first trimester heparin 
infusion. The first INR reading was sub-therapeutic and was corrected. She continued on 2.5mg 
and 5mg alternate days. She was admitted at 36 weeks according to the protocol and was induced 
at 38 weeks. A 2435g baby was delivered by Caesarean section for fetal distress and was thought 
to be growth restricted. The baby progressed well and was discharged from the nursery to the 
mother on day 8.    
 
One baby developed a cephalohaematoma. The most probable cause of this complication was the 
assisted vacuum delivery. This patient had a MVR and was on warfarin 5mg and 7.5mg alternate 
days. She was fully heparinised from 36 weeks according to our protocol and went into 
spontaneous labour at 40 weeks. She had as assisted delivery, vacuum extraction and delivered a 
2580g baby. The baby sustained a cephalohaematoma, but did well, did not develop jaundice and 


















There were 2 cases of maternal valve thrombosis: 3.9 % of the total 51 pregnancies.  
 
The first patient was 35 years old and in her second pregnancy. She had a mechanical aortic 
valve and mechanical mitral valve (the mitral valve had been replaced for the second time in 
1995, 12 years prior to the current pregnancy) and a fistula between the aorta and right atrium. In 
addition to warfarin, she was taking a diuretic, digoxin, spironolactone and an ACE-inhibitor. 
The warfarin dosage was 5mg and 10mg on alternate days. She booked at 24 weeks and had been 
on warfarin throughout the first trimester. She continued on 5mg daily and was well 
anticoagulated with therapeutic INR levels throughout the pregnancy. She was admitted at 32 
weeks and labour was induced at 35 weeks. She delivered by emergency caesarean section at 35 
weeks for fetal distress. She was transferred to the cardiac ward post-delivery for a valve clot.  
 
The second patient was 30 years old. She was a gravida 4 para 3. She had had a MVR 2 years 
prior to the current pregnancy. In addition, she was in chronic atrial fibrillation (AF) and was 
taking and digoxin, spironolactone, atenolol and an ACE-inhibitor. Her warfarin dosage was 
5mg and 7.5mg alternate days. She booked late at 24 weeks and had been on warfarin during the 
first trimester. The first INR recorded was sub-therapeutic. She was put on 5mg and 7.5mg 











and went on to have an emergency caesarean section for pulmonary edema at 32 weeks. A 2115g 
baby was delivered. The patient had an emergency valve replacement day 3 past partum. The 
baby had features consistent with warfarin embryopathy.  
 
There was 1 case of thrombophlebitis. This equates to 2% of patients 
 
This patient was 25 years old. She was in her third pregnancy, and had had a MVR 15 years prior 
to the current pregnancy. She was on warfarin 5mg daily, but had defaulted and was not on 
warfarin when she booked at 26 weeks. The warfarin was restarted and she continued on 5mg 
and 7.5mg alternate days. She was admitted at 36 weeks as per the protocol for continuous 
heparin infusion. She developed a thrombophlebitis. She had a total of 30 days of IVI heparin. 
She went into spontaneous labour at term and delivered a 2870g healthy baby. The patient 
recovered well and was discharged 9 days post partum.  
 
There was 1 case of infective endocarditis: This equates to 2%  
 
This patient was 28 years old. She was in her third pregnancy and had had a MVR 6 year prior to 
the current pregnancy. Her dosage of warfarin was not known at booking at 7 weeks. The first 
INR reading was sub-therapeutic. She had conceived on warfarin and was admitted until 12 
weeks for IVI heparin. She had a total of 38 days in the first trimester on IVI heparin and was 
discharged on warfarin 5mg and 7.5mg alternating days. She was admitted at 37 weeks for IVI 
heparin and had a total of 28 days of IVI administration. She developed an endocarditis, no 











into spontaneous labour at term and delivered a 3450g baby by caesarean section for fetal 
distress. Baby and mother were discharged 8 days post-delivery.    
 
 
 
